Prednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity. (September 2014)

• Record Type: Journal Article
• Authors: Katzer, Tatiele; Chaves, Paula; Bernardi, Andressa; Pohlmann, Adriana; Guterres, Silvia S.; Ruver Beck, Ruy Carlos
• Is Part Of: Journal of microencapsulation. Volume 31:Number 6(2014:Sep.)
• Page Start: 519
• Page End: 528
• Publication Date: 2014-09
• Subjects: Microencapsulation -- Periodicals; Controlled release technology -- Periodicals; 615.19
• DOI: 10.3109/02652048.2013.879930
• Languages: English
• ISSNs: 0265-2048

Abstract

<abstract> <title>Abstract</title> <p> <italic>Objective</italic>: To develop non-toxic aqueous ocular drug delivery systems containing prednisolone by means of its nanoencapsulation. <italic>Materials and methods</italic>: Nanocapsules were prepared by interfacial deposition of preformed polymer [poly(ε-caprolactone) or Eudragit® RS100]. Particle size distribution was determined by laser diffractometry, photon correlation spectroscopy and nanoparticle tracking analysis. Ocular irritation and cytotoxicity were evaluated <italic>in vitro</italic> on the chorioallantoic membrane (CAM) and rabbit corneal epithelial cell line, respectively. <italic>Results and discussion</italic>: Nanocapsules showed mean particle sizes between 100 and 300 nm and prednisolone encapsulation efficiency of around 50%. Controlled release of prednisolone occurred for 5 h for both formulations according to the biexponential model. Both formulations were found to be non-irritant in the CAM test and non-cytotoxic toward rabbit corneal epithelial cells. <italic>Conclusions</italic>: Encapsulation of prednisolone in nanocapsules was reported for the first time, being suitable for producing eye drops for the treatment of ocular inflammatory and no eye toxicity was indicated.</p> </abstract>